List view / Grid view
There has been a continuous move by the large commercially orientated players involved in Drug Discovery to initiate novel methods to increase income streams and productivity. An example of the former has been the acquisition of companies and their drug pipelines and in the case of the latter, rationalisation of…
20 March 2009 | By
The 15th annual SBS conference and exhibition will be held in Lille, the capital of the Nord-Pas-de Calais region in Northern France. 2009 is a momentous year for SBS as it is the 15th anniversary of the formation of the Society and to celebrate the occasion this year's theme will…
Peptides and proteins are powerful active therapeutic ingredients used in a wide variety of serious conditions and illnesses such as diabetes, arthritis or cancer. The application of these so-called biopharmaceuticals has been rapidly increasing since the middle of the 1990s, facilitated by improvements in modern recombinant DNA technology and biotechnological…
20 March 2009 | By
On the cold and snowy weekend of the 7th and 8th of February a group of academics, professionals and vendors met in Dublin for the first Cellular Imaging and Analysis event co-hosted by Trinity College Dublin and the European Pharmaceutical Review. Battling through the adverse weather conditions, delegates and speakers…
Quality risk management (QRM) is an important part of science-based decision making which is essential for the quality management of pharmaceutical manufacturing1. The ICH Q9 guideline, Quality Risk Management2 defines QRM as a systematic process for the assessment, control, communication and review of risk to the quality of drug product…
20 March 2009 | By
Back for the 29th time, Achema 2009 will be the worldwide leading event for chemical engineering and the process industries. With 4,000 exhibitors from every continent, 180,000 participants from 100 countries and 30,000 executives, it is set to be a huge affair. Some of the exhibitors include:
20 March 2009 | By
The program will begin on Sunday 31 May with tutorial lectures at 5pm and the opening session and plenary lecture at 6.45pm. The tutorial lectures will be given by:
7 February 2009 | By
For plants and invertebrates, RNA interference is firmly established as an important antiviral mechanism. Even before Fire, Mello, and co-workers described RNA interference (RNAi) in worms in 19981 it was becoming clear that plants have an RNA-dependent pathway that protects against viral infections2. The pathway, then termed post-transcriptional gene silencing…
7 February 2009 | By Tania Nolan, Global Manager, Sigma-Aldrich and Stephen Bustin, Professor of Molecular Science, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry
The fluorescence-based quantitative real-time polymerase chain reaction (qPCR)1-3, has the ability to detect and measure minute amounts of DNA in a wide range of samples extracted from numerous sources. In combination with reverse transcription (RT), the use of this technology has revolutionised life sciences, agriculture and medical research4,5. In addition,…
7 February 2009 | By
High Content Analysis and Screening technologies (HCA) ushered in a new era in the biomedical research, enabling the scientists to uncover previously unknown disease mechanisms and to introduce innovative approaches to the development of the new generations of therapeutic drugs with a potential to selectively target individual genes, molecules and…
7 February 2009 | By
Cellular Imaging and Analysis is undoubtedly one of the hottest topics in the field of pharmaceutical research and development. Technical or diagnostic progress made almost hourly, this multidisciplinary set of challenges and opportunities is proving one of the most profoundly effective in the history of science.
7 February 2009 | By Dr Chris Taylor, Senior Software Engineer, European Bioinformatics Institute and Lennart Martens, Group Co-ordinator of Proteomics Services, European Bioinformatics Institute
There are compelling reasons for regularising the capture and description of proteomics data. Adhering to community-consensus specifications for the annotation of data sets can increase confidence in results and the conclusions drawn upon them, and supports data re-use; working with standard formats and vocabularies can raise efficiency and facilitates sophisticated…
7 February 2009 | By
The current cost of developing a new medicine for the treatment of human disease has been estimated at $1 to $2 billion (€750-1.5 million1,2). Given progressive increases in the cost of developing new drugs, pharmaceutical companies are facing significant pressure to streamline discovery methods and increase the translational efficiency of…
7 February 2009 | By
The ABRF 2009 meeting will present the latest developments in life science technologies and the use of these technologies. Leaders in the field will give presentations including scientific sessions and technical workshops on genomics, proteomics, imaging, and other technologies such as next generation sequencing, genotyping, microarrays, real-time PCR, proteomics and…
7 February 2009 | By
During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.
